Aurisco Pharmaceutical Co Ltd (605116) — Cash Flow Quality Index
Aurisco Pharmaceutical Co Ltd (605116) has a Cash Flow Quality Index of 0.94x as of December 2024. Operating cash flow of CN¥332.41 Million is below net income of CN¥354.79 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Aurisco Pharmaceutical Co Ltd assets under control for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Aurisco Pharmaceutical Co Ltd Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Aurisco Pharmaceutical Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Aurisco Pharmaceutical Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year earnings quality comparison for Aurisco Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see 605116 stock market capitalisation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.94x | CN¥332.41 Million | CN¥354.79 Million | ▼ -29.7% |
| 2023 | 1.33x | CN¥385.61 Million | CN¥289.42 Million | ▲ +66.7% |
| 2022 | 0.80x | CN¥166.41 Million | CN¥208.21 Million | ▼ -33.3% |
| 2021 | 1.20x | CN¥201.57 Million | CN¥168.28 Million | ▼ -12.2% |
| 2020 | 1.36x | CN¥214.48 Million | CN¥157.23 Million | ▲ +41.1% |
| 2019 | 0.97x | CN¥179.90 Million | CN¥186.13 Million | ▲ +20.5% |
| 2018 | 0.80x | CN¥109.77 Million | CN¥136.83 Million | ▼ -69.6% |
| 2017 | 2.64x | CN¥117.91 Million | CN¥44.72 Million | — |